Menu
LAUSANNE, Switzerland, 16 July 2015 – Sophia Genetics, the European leader in Data Driven Medicine (DDM), has today announced three new partnerships with leading Spanish genetic laboratories: Bioarray, Cialab and Genetadi.
Working with these new partners, Sophia Genetics will provide a superior analytical performance solution, to diagnose patients faster and more accurately using advanced technology to de-code the genetic make-up of some common cancers and inherited conditions, such as cystic fibrosis. In addition, Sophia Genetics’ new Spanish partners will adopt the NGS technology in clinical routine more quickly, offering patients the best possible chance of diagnosis and treatment.
Commenting the collaboration, Dr. Luís Alcaráz, Technical Director at Bioarray, explained “We have been working with NGS for genetic diagnosis for several years and our experience tells us that the bioinformatics analysis and genetic variants interpretation are the most critical and time consuming parts of any workflow. With Sophia Genetics’ technology we will be able to speed up the whole process while getting top quality results. This will ultimately benefit the patients, with shorter waiting times.”
José María Alamo, Cialab’s Technical Director also declared “After 20 years in the analytical market as a reference, Cialab has decided to form an alliance with Sophia Genetics. This will allow us to get top analytical performance of NGS results, accelerate the adoption of new NGS tests as routine, reduce the turnaround times and, finally, work with ISO certified high quality bioinformatics tools. Altogether, this alliance will facilitate Cialab in obtaining the ISO 15189 Medical Laboratory accreditation for NGS tests.”
Sophia DDM platform uses the most sophisticated machine learning and algorithms, giving clinicians the most accurate, speedy and cost-effective means of offering genomic analysis of samples to their patients. It is currently the only solution on the European market providing full ISO certification and clinical compliance with EU Data Privacy laws.
José Luís Castrillo, CEO of Genetadi, explained “We have been using Sophia Genetics’ platform for the past few months and I must say it is a friendly, fast, and very powerful informatics tool for the clinical laboratory set up. The company certifications allow us to work with trust and confidence, accelerating our analysis of alterations of the genome DNA, to the benefit of patients”.
In Spain, some 150 clinical laboratories perform genetic tests, but only 60% have adopted NGS technology. Sophia Genetics’ increasing presence in the region should lead to considerable growth in the 15.000 tests already being performed in the country.
Commenting on these partnerships, Jurgi Camblong, CEO and co-founder of Sophia Genetics said “In the near future, we expect other Spanish public and private genetic laboratories to use Sophia DDM platform for NGS clinical data analysis. We see Spain as a growth driver to sustain Sophia Genetics’ strategic objective to reach 100 client institutions by the end of the year”.
The company also announced its expansion in Greece in collaboration with BioAnalytica GenoType SA, which chose Sophia Genetics to reinforce its diagnostic laboratory NGS capabilities in clinical routine. BioAnalytica GenoType SA will now be able to offer a broad range of NGS-based genetic diagnosis tests throughout the whole country at a reduced cost and with a short delivery time.
Thanks to these new partnerships, Sophia Genetics continues to accelerate its footprint: 67 institutions and laboratories in 14 different European countries now use Sophia Genetics’ industry-leading genetic analysis technology to perform fast and accurate clinical interpretation of genetic mutations.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
